

5000-0001
A1
acceptable medium therefor and where the lysine and valine residues contained in said lysine-proline-valine tripeptide sequence can exist either in their levorotatory or dextrorotatory forms.

2. (Amended) The [pharmaceutical/cosmetic composition] method as defined in Claim 1, said tripeptide sequence [being situated at the] comprising the last three amino acids situated at the C-terminal end of said at least one peptide.

3. (Amended) The [pharmaceutical/cosmetic composition] method as defined in Claim 1, said at least one peptide comprising the lysine-proline-valine tripeptide, the proline moiety of which [existing] exists in its dextrorotatory optical isomer form (DPro).

In Claim 4, line 1, change "pharmaceutical/cosmetic composition" to --method--;

line 4, change "existing" to --exists--.

c A2
5. (Amended) The [pharmaceutical/cosmetic composition] method as defined in Claim 1, said at least one peptide including at least one protective group [therefor] situated at the C-terminal and/or ^Nend-terminal end of said peptide.

In Claim 6, line 1, change "pharmaceutical/cosmetic composition" to --method--;

line 2, change "comprising" to --wherein said composition comprises--.

In Claim 7, line 1, change "pharmaceutical/cosmetic composition" to --method--;

line 2, change "comprising" to --wherein said composition comprises--.

In Claim 8, line 1, change "pharmaceutical/cosmetic composition" to --method--;

line 2, change "comprising" to --wherein said composition comprises--.

In Claim 9, line 1, change "pharmaceutical/cosmetic composition" to --method--;

line 2, change "comprising" to --wherein said composition comprises--.

In Claim 10, line 1, change "pharmaceutical/cosmetic composition" to --method--;

line 2, change "comprising" to --wherein said composition comprises--.

In Claim 11, line 1, change "pharmaceutical/cosmetic composition" to --method--;

line 2, change "comprising" to --wherein said composition comprises--.

Kindly cancel Claims 12-15.

Also, please introduce the following additional claims.

e --16. ^{The} A method according to Claim 1, wherein the ~~pharmaceutical/cosmetic~~ composition is topically applied. 13

c a3 17. ^{The} A method according to Claim 1, wherein the pharmaceutical/cosmetic composition is topically applied to the skin, scalp and/or mucous membrane of a mammalian organism. 14

c 18. ^{The} A method according to Claim 1, wherein the pharmaceutical/cosmetic composition ~~which is administered~~ further comprises an effective anti-inflammatory amount of at least one glucocorticoid, vitamin D (or derivative) thereof, and/or non-steroidal anti-inflammatory agent. 15

c 19. ^{The} A method according to Claim 1, wherein said lysine-proline-valine tripeptide sequence ~~contained in said pharmaceu-~~